

JAY CHARLES HORROW, MD, MS, FAHA, FACC

jhorrow@gmail.com

December, 2019

Education:

M.S., Applied Statistics, Villanova University, Villanova, Pennsylvania

M.D., University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

B.S.E., Princeton University, Princeton, New Jersey (High Honors in Electrical Engineering)

Postgraduate Training:

Internship, Internal Medicine, New York Veterans Administration Hospital

Residency, Department of Anesthesia, Hospital of the University of Pennsylvania

Fellowship, Cardiothoracic Anesthesia, Hospital of the University of Pennsylvania

Licensure and Certification:

Diplomate, National Board of Medical Examiners

Diplomate, American Board of Anesthesiology (#9881); voluntary recertification (current)

Licensed Physician in Pennsylvania (current)

Basic and Advanced Life Support, American Heart Association (current)

Industry Positions Held:

Clinical Lead, CV Drug Development, Bristol-Myers Squibb, Lawrenceville, NJ (current)

Executive Director, Global Clinical Development, Merck & Co., North Wales, Pennsylvania

Executive Director, Global R&D, AstraZeneca LP, Wilmington, Delaware

Vice President, Clinical Development, IBEX Technologies Corporation, Montréal, Québec

Academic Positions Held:

Professor, Anesthesiology & Perioperative Medicine, Drexel University College of Medicine

Chairman, Department of Anesthesiology, Drexel University College of Medicine

Professor of Physiology & Pharmacology, Drexel University College of Medicine

Professor of Biostatistics and Epidemiology, School of Public Health, Drexel University

Adjunct Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania

Clinical Professor, Anesthesiology, MCP♦Hahnemann University, Philadelphia, PA

Professor, Anesthesiology, Hahnemann University, Philadelphia, PA

Instructor in Anaesthesia, Harvard Medical School, Brigham & Women's Hospital, Boston

Honors and Awards:

Fellow, American College of Cardiology

Merck Special Achievement Award for Scientific Leader Engagement

AstraZeneca CEO Award for Global Product Team Performance

AstraZeneca US Leadership Team Award for FDA Inspection Conduct

AstraZeneca CEO Award for Genetics Analysis and Publication

Distinguished Performance, AstraZeneca LP, Wilmington, DE

AstraZeneca US Drug Development Innovation Award

Henry Ruth Achievement Award for Anesthesia Education, Drexel University
Fellow, American Heart Association, Council on Cardiothoracic & Vascular Surgery
Alpha Omega Alpha, National Medicine Honor Society, election as faculty member
Tau Beta Pi, National Engineering Honor Society

Major Pharmaceutical Industry Successes

- Label extension, ZONTIVITY[®] (vorapaxar), in EU (type II variation)
- CTD submission, approval/registration of BRILINTA[®] (ticagrelor) globally
- CTD submission, approval/registration of EXANTA[®] (ximelagatran) in EU
- Management, multiple Executive Committees for large-scale cardiovascular outcome trials

Anesthesiology Departmental Leadership:

Director, Division of Cardiothoracic Anesthesia, Hahnemann University

Deputy Chair, Anesthesiology, Hahnemann University

Vice Chair, Anesthesiology, MCP ♦ Hahnemann School of Medicine

Chief, Clinical Operations, Anesthesia, Hahnemann Hospital, Allegheny Univ of Health Sci

Clinical Service Chief, Anesthesia, Hahnemann Hospital, Allegheny Univ of Health Sci

Program Director and Chair, Department of Anesthesiology, Drexel University

University Leadership:

University Library Committee (**Chair** 3 years)

Student Affairs/Scholarship Committee School of Medicine (**Co-chair** 4 years)

Committee for Protection of Human Subjects (IRB; 8 years)

Vice Chair 1 year, **Co-Chair** 3 years, **Chair** 1 year

Chair, Search Committee for Chair, Internal Medicine

Member, Search Committee for Chair, Cardiothoracic Surgery

Chair, University Scientific Misconduct Hearing (Case “HS”)

National Leadership:

For the Society of Cardiovascular Anesthesiologists:

Education Committee (3 years)

Grievance Committee (6 years)

Annual Meeting Scientific Program Committee (8 years); Vice-Chair (2 years); Chair (2 years)

Grader, Abstracts for Annual Scientific Meeting (6 years)

Elected, Board of Directors (3 years)

For the Association of Anesthesia Clinical Directors:

Elected, Treasurer (2 years)

For the American Board of Anesthesiology (accrediting body):

Associate Oral Examiner (25 years)

Editorial Positions:

Associate Editor, *Anesthesiology* (4 years)

Editorial Board, American Journal of Anesthesiology (2 years)

Editorial Board, Journal of Cardiothoracic and Vascular Anesthesia (20 years)

Consultantships

National Board of Medical Examiners
National [Canada] Health Research & Development Program
Medical Research Council [Canada]
ECRI

Patents

US Patent number 8,798,701, "Functional Near-Infrared Spectroscopy as A Monitor For Depth Of Anesthesia," issued August 5, 2014. Drexel Docket No. 07-0868D/P

Scientific Advisory Board Participation and Consultantships:

Johnson & Johnson Pharmaceutical Research & Development
Endo Pharmaceuticals, Chadds Ford, Pennsylvania
GEM Pharmaceuticals, Pelham, Alabama
IBEX Technologies, Montreal, Quebec, Canada and Malvern, Pennsylvania
International Technidyne Corporation, Edison, New Jersey
Repligen Corporation, Cambridge, Massachusetts

Active Memberships in Professional Societies

American Society of Anesthesiologists
International Anesthesia Research Society
Association of University Anesthesiologists
American College of Cardiology
American Heart Association, professional level membership

Competitive Grants:

Parker B. Francis Foundation, *via* American Society of Anesthesiologists: Neuromuscular Junction Studies of Rat Diaphragm. **Principal Investigator**
Mary L. Smith Charitable Lead Trust: Pharmacologic Control of Bleeding after Open Heart Surgery. (\$45,500) **Principal Investigator**
Mary L. Smith Charitable Lead Trust: Pharmacologic Control of Bleeding: Dose-Response Aspects. (\$54,500) **Principal Investigator**
Mary L. Smith Charitable Lead Trust: Tranexamic Acid Protects Platelets during Cardiopulmonary Bypass. (\$52,000) **Principal Investigator**

Commercially sponsored Grants:

- Mon-A-Therm, Inc (St. Louis, MO): Thermal Disequilibrium and Cardiopulmonary Bypass. (\$2,700) **Principal Investigator**
- Akzo, Inc: Pipecuronium v. Pancuronium during Open Heart Surgery. (\$47,063) **Principal Investigator**
- Miles, Inc.: Efficacy and Safety of Aprotinin in Reducing Blood Loss and Transfusion Requirement in Patients under-going Repeat Myocardial Revascularization (\$153,720) **Principal Investigator**
- Akzo, Inc.: Which Relaxant is Optimal for Opioid Anesthesia? (\$59,385) Associate Investigator
- Gensia Pharmaceuticals: A randomized double blind controlled study of the effect of acadesine in myocardial infarction and averse cardiovascular outcomes in patients undergoing coronary artery bypass graft (CABG) surgery (\$90,000), **Co-investigator**
- Zeneca Pharmaceuticals: The effects of Zeneca ZD0859#1 versus Diprivan (Propofol) injection on electrolytes and hemodynamic stability when each is used with high dose or low dose opioid for cardiac surgery. (\$47,090) **Principal Investigator**
- Abbott Laboratories: A phase III multi-center, double-blind, randomized comparative study evaluating the effects of two doses of dexmedetomidine versus placebo in adult patients undergoing elective CABG. (\$120,000) Associate Investigator
- IBEX Technologies: An open label, phase II dose ranging study of Neutralase in patients undergoing coronary artery bypass grafting. (\$87,000) **Principal Investigator**
- IBEX Technologies: Comparison of Neutralase with protamine in patients under-going coronary artery bypass graft surgery. (\$68,500) **Principle Investigator**
- GlaxoSmithKline: A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis. **Principle Investigator**
- Merck: A randomized, double-blind comparison of oral aprepitant alone vs oral aprepitant and transdermal scopolamine for preventing postoperative nausea and vomiting. (\$40,020) **Principal Investigator**

Bibliography Summary: 114 articles in peer-reviewed journals
42 book chapters plus 1 edited monograph
12 editorials and 27 miscellaneous monographs
>100 scientific abstracts and 25 letters to the editor
NOTE: Bibliographic summary may be incomplete.

BIBLIOGRAPHY

Articles in Peer-Reviewed Journals: (* =original research; others: case reports or reviews)

1. Schwartz AJ, Horrow JC, Jobes DR, Ellison N: Guide Wires - A Caution. Crit Care Med **9**:347-348, 1981.
2. Horrow JC, Laucks SO: Coronary Air Embolism during Venous Cannulation. Anesthesiology **56**:212-214, 1982.
3. * Horrow JC, Bartkowski RR: Pancuronium, unlike other non-depolarizing relaxants, retains potency at hypothermia. Anesthesiology **58**: 357-361, 1983.
4. * Metz S, Horrow JC, Balcar I: A Controlled Comparison of Techniques for Locating the Internal Jugular Vein Using Ultrasonography. Anesth Analg **63**: 673-679, 1984.
5. * Horrow JC, Lambert DL: The Search for an Optimal Interval Between Pretreatment Dose of d-Tubocurarine and Succinylcholine. Can Anaesth Soc J **31**:528-533, 1984.
6. Raemer D, Horrow JC, Mark JB, Maddi R, Collins JJ, LeeSon S: A New Surgical Monitoring and Resuscitation Cart. Med Instr **18**:189-190, 1984.
7. Horrow JC: Thrombocytopenia Accompanying a Reaction to Protamine Sulfate. Can Anaesth Soc J **32**:63-66, 1985.
8. Horrow JC: Protamine – A Review of its Toxicity. Anesth Analg **64**:348-361, 1985.
9. * Horrow JC, Metz S, Thickman D, Frederic MW: Prior Carotid Surgery Does Not Affect the Reliability of Landmarks for Locating the Internal Jugular Vein. Anesth Analg **66**:452-456, 1987.
- 10.* Horrow JC, Jaffe JR, Rosenberg H: A Laboratory Evaluation of Resistive Intravenous Flow Regulators. Anesth Analg **66**:660-665, 1987.
11. Litwack RS, Horrow JC: Lethal Thrombosis during Coronary Artery Bypass Surgery. Anesthesiology **66**:134-136, 1987.
- 12.* Mark JB, Horrow JC, Eckenbrecht PD, Smalky M, Arthur GR, Dhingra U, Murray E: Anesthetic induction with fentanyl and intravenous lidocaine for coronary surgery. J Cardiothorac Anesth, **1**:517-523, 1987.
13. Horrow JC: Protamine Allergy. J Cardiothorac Anesth **2**:225-242,1988.
14. Crell A, Horrow JC, Barker SJ, Hessel EA: Malfunction of an Intra-aortic Balloon Detected by Oximetry [Case Conference 5-1988]. J Cardiothoracic Anesth **2**: 693-700, 1988.

- 15.* Horrow JC, Rosenberg H: Does Urinary Catheter Temperature Reflect Core Temperature During Cardiac Surgery? *Anesthesiology* **69**:986-989, 1988.
- 16.* Weiss ME, Nyhan D, Peng Z, Horrow JC, Lowenstein E, Hirshman C, Adkinson NF: Association of Protamine IgE and IgG Antibodies with Life-threatening Reactions to Intravenous Protamine. *N Engl J Med* **320**:886-892, 1989.
17. Horrow JC, Lingaraju N: Unexpected persistent left superior vena cava: diagnostic clues during monitoring. *J Cardiothoracic Anesth* **3**: 611-615, 1989.
- 18.* Horrow JC, Hlavacek J, Strong MD, Collier W, Brodsky I, Goldman SM, Goel IP: Prophylactic tranexamic acid decreases bleeding following cardiac surgery. *J Thorac Cardiovasc Surg* **99**:70-74, 1990.
- 19.* Horrow JC, DiGregorio GJ, Barbieri EJ, Rupp E: Intravenous infusions of nitroprusside, dobutamine, and nitroglycerin are compatible. *Crit Care Med* **18**: 858-861, 1990.
- 20.* Maddi R, Horrow JC, Mark JB, Concepcion M, Murray E: Evaluation of a new cutaneous topical anesthetic preparation. *Reg Anesth* **15**:109-112, 1990.
- 21.* Van Riper DF, Horrow JC, Kutalek SP, McCormick D, Goldman SM: Mixed venous oxygen saturation during cardiac arrest. *J Cardiothoracic Anesth* **4**:453-457, 1990.
22. Campbell FW, Tyson GS, Gravlee GP, Horrow JC, Tuman KJ : A 66-year old woman who is taking aspirin continues to bleed after routine care [Case Conference 4-1990]. *J Cardiothoracic Anesth* **4**:499-517, 1990.
- 23.* Allen G, Horrow JC, Rosenberg H: Does forehead liquid crystal temperature reflect core temperature? *Can J Anaesth* **37**:659-662, 1990.
24. Horrow JC, Pharo G: Successful defibrillation with near-simultaneous orthogonal discharges. *Anesthesiology* **75**:362-364, 1991
- 25.* Soslau G, Horrow JC, Parker J, Brodsky I: The effect of tranexamic acid on platelet ADP during extracorporeal circulation. *Am J Hematol* **38**:113-119, 1991
- 26.* Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL: The hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. *Circulation* **84**:2063-2070, 1991.
- 27.* Horrow JC, Abrams JT, Van Riper DF, Lambson D, Storella RJ: Static ventilatory compliance after three sufentanil-pancuronium induction sequences. *Anesthesiology* **75**:969-974, 1991.
28. Cook RI, Woods DD, Howie MB, Horrow JC, Gaba DM: Unintentional delivery of vasoactive drugs with an electromechanical infusion device. *J Cardiothoracic Vasc Anesth* **6**:238-244, 1992.

- 29.* Okum GS, Colonna-Romano P, Horrow JC: Vomiting after alfentanil anesthesia: Effect of dosing method. *Anesth Analg* **75**:558-560, 1992
- 30.* Bennett JA, Lingaraju N, Horrow JC, McElrath T, Keykhah MM: Elderly patients recover more rapidly from desflurane than from isoflurane anesthesia. *J Clin Anesth* **4**:378-381, 1992.
- 31.* Parmet JL, Berman AT, Horrow JC, Harding S, Rosenberg H: Thromboembolism coincident with tourniquet deflation during total knee arthroplasty. *Lancet* **341**:1057-1058, 1993
32. Pharo GH, Horrow J, Van Riper D, Levy JH: Suspected Protamine Allergy: Diagnosis and Management for Coronary Artery Surgery. *Anesth Analg* **78**:181-184, 1994
33. Metz S, Horrow J: CPB and alterations in hemostasis: New strategies for management. *Sem Anesth* **13**:50-56, 1994
- 34.* Colonna-Romano P, Horrow JC: Dissociation of mixed venous oxygen saturation and cardiac index during opioid induction. *J Clin Anesth* **6**:95-98, 1994
- 35.* Lingaraju N, Horrow JC, Colonna-Romano P, Strong MD: Haemodynamic consequences of warm cardiac irrigation during coronary artery surgery. *Can J Anaesth* **41**:384-386, 1994
- 36.* Siler JN, Horrow JC, Rosenberg H: Propofol reduces prolonged outpatient PACU stay. *Anesth Rev* **21**:129-132, 1994
- 37.* Horrow JC, DiGregorio GJ, Ruch E: The dose-plasma concentration relationship of tranexamic acid during surgery. *Am J Therapeutics* **1**:206-209, 1994
- 38.* Horrow JC, Rosenberg H: Price stickers do not affect drug usage. *Can J Anaesth* **41**:1047-1052, 1994
39. * Parmet J, Horrow JC, Singer R, Berman AT, Rosenberg H: Echogenic emboli upon tourniquet release during total knee arthroplasty: Pulmonary hemodynamic changes and embolic composition. *Anesth Analg* **79**:940-945, 1994
40. Parmet JL, Horrow JC, Keykhah MM, Sirianni A, Singer R, Weiss A: Accumulation of a right ventricular mass during shoulder hemiarthroplasty. *Anesth Analg* **80**:614-616, 1995
- 41.* Horrow JC, Van Riper DF, Strong MD, Grunewald K, Parmet JL: The dose-response relationship of tranexamic acid for hemostasis after extracorporeal circulation. *Anesthesiology* **82**: 383-392, 1995
42. * Parmet JL, Horrow JC, Pharo G, Collins L, Berman AT, Rosenberg H: The incidence of venous emboli during extramedullary guided total knee arthroplasty. *Anesth Analg* **81**:757-762, 1995
43. * Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith P, Nadel A, Bonney SL, Kleinfeld R: A multicenter, double-blind, placebo-

- controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. *Circulation* **92**: 2236-2244, 1995
44. * Storella RJ, Kandell RB, Horrow JC, Ackerman TS, Polansky M, Zeitz S: Nonlinear measures of heart rate variability after fentanyl-based induction of anesthesia. *Anesth Analg* **81**:1292-1294, 1995
 45. * Horrow JC, Pharo G, Levit LS, Freeland CA: Neither skin tests nor serum ELISA tests provide specificity for protamine allergy. *Anesth Analg* **82**:386-389, 1996
 46. * Okum GS, Hauser AC, Keykhah MK, Horrow JC: Sufentanil plasma concentrations following lower extremity tourniquet release. *J Clin Anesth* **8**: 210-215, 1996
 47. * Bennett JA, Horrow JC: Activated coagulation time: One tube or two? *J Cardiothorac Vasc Anesth* **10**:471-473, 1996
 48. * Metz S, Horrow JC, Goel IP, Kuretu MRL, Bellwoar C: Methylene blue does not neutralize heparin after cardiopulmonary bypass. *J Cardiothorac Vasc Anesth* **10**:474-476, 1996
 49. * Pan C-M, Van Riper DF, Horrow JC, LaDuca F: A modified microsample ACT test for heparin monitoring. *J Extracorp Technol* **28**: 16-20, 1996
 50. * Abrams JT, Horrow JC, Bennett JA, Storella RJ, Van Riper DF: Upper Airway Closure: A primary source of difficult ventilation with sufentanil induction. *Anesth Analg* **83**: 629-632, 1996
 51. * Bennett JA, Horrow JC, Abrams JT, Van Riper DF: Difficult or impossible ventilation after sufentanil-induced anesthesia is caused primarily by vocal cord closure. *Anesthesiology* **87**:1070-1074, 1997.
 52. * Brozena SC, Morris R, Samuels L, Horrow J, Peterson P, Siegel J, Twomey C: Heart transplantation in patients with heparin-induced thrombocytopenia on the Novacor left ventricular assist system. *J Heart Lung Transplant* **17**: 729-731, 1998.
 53. * Parmet JL, Colonna-Romano P, Horrow JC, Miller F, Gonzales J, Rosenberg H: The laryngeal mask airway reliably provides rescue ventilation in cases of unanticipated difficult tracheal intubation along with difficult mask ventilation. *Anesth Analg* **87**: 661-665, 1998.
 54. * Berman AT, Parmet JL, Harding SP, Israelite CL, Chandrasekaren K, Horrow JC, Singer R, Rosenberg H: Emboli observed with use of transesophageal echocardiography immediately after tourniquet release during total knee arthroplasty with cement. *J Bone Joint Surg Am.* **80**: 389-396, 1998.
 55. * Parmet JL, Horrow JC, Berman AT, Miller F, Pharo G, Collins L: The incidence of large venous emboli during total knee arthroplasty without pneumatic tourniquet use. *Anesth Analg* **87**: 439-444, 1998.

56. Robinson D, Parmet JL, Horrow JC: Coagulation Emergencies. *Sem Anesth Perioper Med Pain* 17: 111-120, 1998.
- 57.* Storella RJ, Horrow JC, Polansky M: Differences among heart rate variability measures after anesthesia and cardiac surgery. *J Cardiothoracic Vasc Anesth* 13: 451-453, 1999.
58. Urdaneta F, Lobato EB, Kirby RR, Horrow JC: Noncardiogenic pulmonary edema associated with protamine administration during coronary artery bypass graft surgery. *J Clin Anesth* 11: 675-681, 1999.
59. Horrow JC. Uncommon coagulation problems. *Adv Cardiac Surg* 12: 153-168, 2000.
- 60.* Wahr J, Vender J, Gilbert HC, Spiess B, Horrow JC, Maddi R. Effect of propofol with and without EDTA on haemodynamics and calcium and magnesium homeostasis during and after cardiac surgery. *Intensive Care Med* 26(Suppl 4): S443-51, 2000.
61. Mukadam ME, Pritchard P, Riddington D, Wilkes M, Graham, TR, Horrow JC, Spiess BD: Management during cardiopulmonary bypass of patients with presumed fish allergy. *J Cardiothoracic Vascular Anesth* 15: 512-519, 2001
- 62.* Heres EK, Horrow JC, Gravlee GP, Tardiff B, Lubner J, Schneider J, Barragry T, Broughton R: A dose-determining trial of heparinase-I (Neutralase™) for heparin neutralization in coronary artery surgery. *Anesth Analg* 93: 1446-1452, 2001
- 63.* Horrow MM, Horrow JC, Niakosari A, Kirby CL, Rosenberg HK: Is age associated with size of adult extrahepatic bile duct: A sonographic study. *Radiology* 221:411-414, 2001
- 64.* Horrow MM, White D, Horrow JC: Differentiation of perforated from nonperforated appendicitis at CT. *Radiology* 227:46-51, 2003. PMID 12615997
- 65.* Halperin JL and the Executive Steering Committee: Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). *Am Heart J* 146:431-8, 2003. [Horrow JC is a member of the Executive Steering Committee and an author of this paper]
- 66.* Executive Steering Committee on behalf of the SPORTIF III investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III). *Lancet* 362:1691-8, 2003. [Horrow JC is a member of the Executive Steering Committee and an author of this paper]
- 67.* Chamchad D, Arkoosh V, Horrow JC, Buxbaum J, Izrailtyan I, Nakhamchik L, Hoyer D, Kresh JY: Risk Stratification of Obstetric Patients undergoing Spinal Anesthesia. *Anesth Analg* 99: 1818-21, 2004

68. * Schwann NM, Horrow JC, Strong MD, Chamchad D, Guerraty A, Weschler AS: Renal dysfunction in multivessel myocardial revascularization: Does the off pump technique confer renal protection? *Anesth Analg* 2004; **99**:959-64
69. * Executive Steering Committee for the SPORTIF V investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF V). *JAMA* 2005; **293**: 690-8 [Horrow JC is a member of the Executive Steering Committee and an author of this paper]
70. * Liddle RA, Toskes PP, Horrow J, Ghali J, Dachman A, Stong D: Lack of Trophic Pancreatic Effects in Humans with Chronic Administration of Ximelagatran. *Pancreas* 2006; **32**: 205-10
71. * Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation. An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. *Am Heart J* 2006; **152**: 967-73
72. * Chamchad D, Djaiani, Jung HJ, Nakhamchik L, Carroll J, Horrow JC: Nonlinear heart rate variability analysis may predict atrial fibrillation after coronary artery bypass grafting. *Anesth Analg* 2006; **103**: 1109-12 PMID 17056940
73. * Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J: Comparison of Bleeding in Patients with Nonvalvular Atrial Fibrillation Treated With Ximelagatran or Warfarin. *Arch Int Med* 2006; **166**:853-9
74. * Chamchad D, Horrow J, Arkoosh VA, Nakhamchik L: Heart Rate Variability Changes during Pregnancy: an Observational Study. *Int J Obstet Anesth* 2007; **16**: 106-9
75. * Baruch L, Gage B, Horrow J, Juul-Möller S, Labovitz A, Persson M, Zabalgoitia M: Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified? A Comparison of 7 Stroke Prediction Schemes. *Stroke* 2007; **38**:2459-63
76. Green MS, Horrow J: Ventilatory management of the patient with hyperimmunoglobulinemia E (Job) syndrome. *J Clin Anesth* 2008; **20**: 133-5 PMID 18410869
77. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, French PA, Dauerman HL, Becker RC, 2009 Platelet Colloquim Participants (Horrow JC included). Platelet functions beyond hemostasis. *J Thromb Haemost* 2009; **7**: 1759-66
78. * Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Story RF, Harrington RA, PLATO Investigators, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009; **361**: 1045-57
79. Rao SV, Eikelboom J, Steg PG, Lincoff AM, Weintraub WS, Bassand JP, Rao AK, Gibson CM, Petersen JL, Mehran R, Manoukian SV, Charnigo R, Lee KL, Moscucci M, Harrington RA,

- Academic bleeding consensus multidisciplinary working group (Horrow J included). Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes. A proposal from the academic bleeding consensus (ABC) multidisciplinary working group. *Am Heart J* 2009; **158**: 881-6e1
80. Phon H, Jaffe J, Horrow J. Perioperative management of acute ischemic stroke. A case report. *J Clin Anesth* 2009; **21**: 602-5 [PMID 20122594]
 81. Parva M, Chamchad D, Keegan J, Gerson A, Horrow J. Placenta percreta with invasion of the bladder wall. Management with a multi-disciplinary approach. *J Clin Anesth* 2010; **22**: 209-12 [PMID 20400009]
 82. * Chamchad D, Horrow J, Nachamchik L, Sutter FP, Samuels LE, Trace CL, Ferdinand F, Goldman SM. The impact of immediate extubation in the operating room after cardiac surgery on intensive care and hospital lengths of stay. *J Cardiothorac Vasc Anesth* 2010; **24**: 780-4. [PMID 20650657]
 83. * Grammes JA, Schulze CM, Al-Bataineh M, Tesenosky GA, Saari CS, Vrabel MJ, Horrow J, Chowdhury M, Fontaine JM, Kutalek SP. Percutaneous pacemaker and implantable cardioverter defibrillator lead extraction in 100 patients with intracardiac vegetations defined by transesophageal echocardiogram. *J Am Coll Cardiol* 2010; **55**: 886-94. [PMID 20185039]
 84. * Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. *Lancet* 2010; **376**: 1320-8. [PMID 20801498]
 85. * James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. *Circulation* 2010; **122**: 1056-67. [PMID 20805430]
 86. * Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. *J Am Coll Cardiol* 2011; **57**: 672-84
 87. * James SK, Roe MT, Cannon CP, Cornel JH, Emanuelsson H, Horrow J, Husted S, Katus H, Morais J, Pieper KS, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington R. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management – a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. *BMJ* 2011; **342**:d3527. [PMID 21685437]

88. * Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L; on behalf of the PLATO Investigators. Ticagrelor Compared to Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. *Circulation* 2011; **124**: 544-54
89. * Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, Jopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L. Bleeding Complications with the P2Y12 Receptor Antagonists Clopidogrel and Ticagrelor in the PLATelet Inhibition and Patient Outcomes (PLATO) Trial. *Eur Heart J* 2011; **32**: 2933–44. [PMID 22090660]
90. * Chamchad D, Horrow JC, Samuels LE, Nakhamchik L. Heart rate variability measures poorly predict atrial fibrillation after off-pump coronary artery bypass grafting. *J Clin Anesth* 2011; **23**: 451-5. [PMID 21911190]
91. * Chamchad D, Horrow JC, Nakhamchik L, Sauter J, Roberts N, Aronzon B, Gerson A, Medved M. Prophylactic glycopyrrolate prevents bradycardia after spinal anesthesia for Cesarean section. A randomized, double-blinded, placebo-controlled prospective trial with heart rate variability correlation. *J Clin Anesth* 2011; **23**: 361-6 [PMID 21632228]
92. * Varenhorst C, Alström U, Scirica BM, Hogue CW, Asenblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held C. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. *J Am Coll Cardiol.* 2012; **60**: 1623-30. [PMID 23021325]
93. * Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L; for the PLATO study group. Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes: A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial. *Circ Cardiovasc Qual Outcomes.* 2012;**5**:680-8. [PMID 22991347]
94. * Cornel JH, Becker RC, Goodman SG, Husted S, Katus H, Santoso A, Steg G, Storey RF, Vintila M, Sun JL, Horrow J, Wallentin L, Harrington R, James S. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes- Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. *Am Heart J* 2012; **164**:334-42. [PMID 22980299]
95. * Green MS, Green P, Malayaman SN, Hepler M, Neubert LJ, Horrow JC. Randomized, double-blind comparison of oral aprepitant alone compared with aprepitant and transdermal scopolamine for prevention of postoperative nausea and vomiting. *Br J Anaesth* 2012; **109**:716-22 [PMID 22831888]

96. * Armstrong PW, Siha H, Fu Y, Westerhout CM, Steg PG, James SK, Storey RF, Horrow J, Katus H, Clemmensen P, Harrington RA, Wallentin L. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. *Circulation* 2012; 125:514-21. [PMID 22179530]
97. * Akerblom Å, Wallentin L, Siegbahn A, Becker RC, Budaj A, Buck K, Giannitsis E, Horrow J, Husted S, Katus HA, Steg PG, Storey RF, Åsenblad N, James SK. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. *Clin Chem* 2012; 58:190-9. [PMID 22126936]
98. * Varenhorst C, Alstrom U, Scirica BM, Hogue CW, Asenblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, Hames S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held C. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. *JACC* 2012; 60:1623-30. [PMID 23021325]
99. * Akerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Horrow J, Husted S, Katus H, Claeys MJ, Storey RF, Asenblad N, James SK. Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients – results from the PLATElet inhibition and patient Outcomes (PLATO) study. *Am Heart J* 2012; 164:728-34. [PMID 23137503]
- 100.* Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP. Reduction in First and Recurrent Cardiovascular Events with Ticagrelor Compared with Clopidogrel in the PLATO Study. *Circulation* 2013; 127: 673-80. [PMID 23277305]
- 101.* Kohut AR, Grammes J, Schulze CM, Al-Bataineh M, Yesenosky GA, Horrow JC, Kutalek SP. Percutaneous Extraction of Coated-Coil ICD Leads: A Single Center Comparative Experience. *Pacing Clin Electrophysiol.* 2013; 36: 444-50. [PMID 23330676]
- 102.*Akerblom A, Wallentin L, Larsson A, Siegbahn A, Becker RC, Budaj A, Himmelmann A, Horrow J, Husted S, Storey RF, Asenblad N, James SK. Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATElet Inhibition and Patient Outcomes (PLATO) study. *Clin Chem* 2013; 59: 1369-75. [PMID 23698074]
- 103.*Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington RA, Gibson CM. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). *JACC Cardiovasc Interv* 2013; 6: 671-83. [PMID 23866179]
- 104.*Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, Himmelmann A, Horrow J, Katus HA, Lassila R, Morais J, Nicolau JC, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATO study group. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATElet inhibition and patient Outcomes (PLATO) trial. *Eur Heart J* 2014; 35: 1541-50. [PMID 24682844]

- 105.* Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J, Husted S, Mahaffey KW, Steg PG, Storey RF, Wallentin L, James SK. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel. Data from the PLATO Trial. *Eur J Prev Cardiol* 2015; 22: 734-42. [PMID 24830710]
- 106.* Ycas JW, Horrow JC, Horne BD. Persistent increase in red cell size distribution width after acute diseases: A biomarker of hypoxemia? *Clin Chim Acta* 2015; 448: 107-17 [PMID 26096256]
- 107.* Gorbachova T, Wang PS, Hu B, Horrow JC. Plantar talar head contusions and osteochondral fractures: associated findings on angle MRI and proposed mechanism of injury. *Skeletal Radiol* 2016; 45:795-803 [PMID 26969200]
- 108.* Kraft WK, Gilmartin JH, Chappell DL, Gheyas F, Walker BM, Nagalla S, Naik UP, Horrow JC, Wrishko RE, Zhang S, Anderson MS. Effect of vorapaxar alone and in combination with aspirin on bleeding time and platelet aggregation in healthy adult subjects. *Clin Transl Sci* 2016; 9:221-7. [PMID 27304196]
- 109.* Pressman GS, Matejkova M, Horrow JC, Pai RG. Prevalence and Clinical Significance of an E-Reversal Wave in the Left Ventricular Outflow Tract. *Am J Cardiol* 2016; 118: 1593-7. [PMID 27666176]
- 110.* Mahon V, Chamchad D, Horrow JC, Gerson A, Brest N. A randomized double-blind comparison of IV ibuprofen vs IV ketorolac to prevent postoperative pain after scheduled Cesarean section. *Int J Health Sci* 2016; 4: 1-6. [no PMID]
- 111.* Mezue K, Goyal A, Pressman GS, Horrow JC, Rangaswami J. Blood pressure variability predicts adverse events and cardiovascular outcomes in chronic kidney disease: A post-hoc analysis of the SPRINT trial. *Am J Hypertens* 2017; 31:48-52 [PMID 28985328]
- 112.* Mezue K, Goyal A, Pressman G, Matthew R, Horrow JC, Rangaswami J. Blood pressure variability predicts adverse events and cardiovascular outcomes in SPRINT. *J Clin Hypertens* 2018; doi: 10.1111/jch.13346. [Epub ahead of print] [PMID 29984884]
- 113.* Cohen M, Cerniglia B, Gorbachova T, Horrow J. Added value of MRI to X-ray in guiding the extent of surgical resection in diabetic forefoot osteomyelitis: a review of pathologically proven, surgically treated cases. *Skeletal Radiol* 2019; 48: 405-11. [PMID 30136224]
- 114.* Verma M, Horrow J, Navarro V. A behavioral health program for alcohol use disorder, substance abuse, and depression in chronic liver disease. *Hepatol Commun* 2019; 3: 646-655. [PMID pending]

Books / Periodicals / Monographs Edited:

Horrow JC (ed.): Pharmacology of Blood and Haemostasis. *Anaesth Pharmacol Rev* **3**(2): 1995.

Book Chapters:

1. Horrow JC: Adverse Responses to Protamine Sulfate. In: Anaphylactoid Reactions in Anesthesia (Sage D, ed.) *Int Anesth Clin* **23**:133-143, 1985.
2. Horrow JC: Protamine: A Necessary Evil? In Ellison N, Jobes DR (eds): Effective Hemostasis in Cardiac Surgery, Philadelphia, Saunders, 1988, p 15-39.
3. Horrow JC, Seitman DT: Electrical Safety and Device Calibration. In: Barash PG (ed): Cardiac Monitoring. *Anesthesiology Clinics of North America*, Philadelphia, Saunders, **6**:699-720, 1988.
4. Horrow JC, Hensley FA, Merin RG: Anesthetic Management for Myocardial Revascularization. In: Hensley FA, Martin D: The Practice of Cardiac Anesthesia, Boston, Little Brown, 1990: p 325-349.
5. Horrow JC, Padolina RP: General Anesthetics. In: DiPalma JR, DiGregorio GJ (eds): Basic Pharmacology in Medicine, 3rd ed, New York, McGraw Hill, 1990: p 195-208.
6. Horrow JC: Desmopressin and Antifibrinolytics. In: Gravlee G (ed.): Blood Conservation Int Anesth Clin, **48**(4): 230-236, Fall 1990.
7. Rosenberg H, Horrow JC: Causes and Consequences of Hypo- and Hyperthermia. In: Benumof J, Saidman L (eds.): Anesthesia and Perioperative Complications, St. Louis: Mosby, 1991: p 337-355.
8. Horrow JC: Causes of bleeding after cardiac surgery. In: Baron JF, Samama ChM (eds.): Hémorragies au Bloc Opératoire (J.E.P.U.). Paris: Arnette, 1992: 31-45
9. Horrow JC: Antifibrinolytic therapy and approach to the bleeding patient. In: Baron JF, Samama ChM (eds.): Hémorragies au Bloc Opératoire (J.E.P.U.). Paris: Arnette, 1992: 305-318
10. Horrow JC: Management of Coagulation and Bleeding Disorders. In: Kaplan JA: Cardiac Anesthesia, 3rd ed. Philadelphia: Saunders, 1993: 951-994
11. Horrow JC: Management of Coagulopathy Associated with Cardiopulmonary Bypass. In: Gravlee GP, Utley JR, Davis RF: Principles and Practice of Cardiopulmonary Bypass, Baltimore: Williams and Wilkins, 1993: 436-466.
12. Horrow JC: Electrical Safety. In: Kirby RR, Gravenstein N: Clinical Anesthesia Practice, Philadelphia: Saunders, 1994: 885-896.

13. Horrow JC: Hemostatic agents revisited. In: Ornstein E (ed): New Drugs in Anesthesia. Anesthesiology Clinics of North America, Philadelphia, Saunders, 12:91-117, 1994.
14. Metz S, Horrow JC: Protamine and newer heparin antagonists. In: Stoelting R (ed.) Pharmacology and Physiology in Anesthetic Practice Updates. Philadelphia: Lippincott. 1(3):1-15, 1994.
15. Horrow JC, Hensley FA, Merin RG: Anesthetic Management for Myocardial Revascularization. In: Hensley FA, Martin D: A Practical Approach to Cardiac Anesthesia, 2nd ed., Boston, Little Brown. 1995: 275-295.
16. Metz S, Horrow JC: Pharmacologic Manipulation of Coagulation: Protamine and other Heparin Antagonists. In: Lake CL, Moore RA (eds.): Blood: Hemostasis, transfusion and alternatives in the perioperative period. New York: Raven Press. 1995:119-130
17. Bartkowski RR, Horrow JC: Complications Associated with Muscle Relaxants. In: Gravenstein N, Kirby RR: Complications in Anesthesiology, 2nd ed. Philadelphia: Lippincott. 1996:661-678
18. Metz S, Horrow JC: Update on Aprotinin and Other Drugs to Promote Coagulation. In: Lake CL, Rice LJ, Sperry RJ (ed.): Advances in Anesthesia, Volume 13, Chicago, Mosby-Year Book, 1996: 355-393
19. Horrow MM, Horrow JC: Perioperative complications of cemented prosthesis. In: Langeron O, Riou B (eds.): L'anesthésie pour chirurgie orthopédique, Paris: Arnette. 1997: 55-68
20. Horrow JC: Perioperative bleeding control in orthopedic surgery. In: Langeron O, Riou B (eds.): L'anesthésie pour chirurgie orthopédique, Paris: Arnette. 1997: 21-32
21. Parmet JL, Horrow JC: Hematological Diseases. In: Benumof J (ed.): Anesthesia and Uncommon Diseases, 4th ed. Philadelphia: Saunders. 1997: 275-315.
22. Horrow JC: Intraoperative Coagulation Disorders. In: Thomas SJ, Kramer J (eds.): Manual of Cardiac Anesthesia, 3rd ed. New York: Churchill Livingstone. 1997: (in press).
23. Horrow JC, Padolina RP: General Anesthetics. In: DiPalma JR, DiGregorio GJ (eds): Basic Pharmacology in Medicine, 4th ed, New York: McGraw Hill. 1997: (publication aborted).
24. Horrow JC: Transfusion Medicine and Coagulation Disorders. In: Kaplan JA: Cardiac Anesthesia, 4th ed. Philadelphia: Saunders, 1999:1111-1154.
25. Ellison N and Horrow JC: Coagulation and Coagulopathies. In: Youngberg JA (ed.) Cardiac, Vascular, and Thoracic Anesthesia. New York: Churchill Livingstone. 2000: 779-791.

26. Horrow JC and Fitch JKC: Management of Coagulopathy Associated with Cardiopulmonary Bypass. In: Gravlee GP, Utley JR, Davis RF (eds.): Principles and Practice of Cardiopulmonary Bypass, 2nd edition, Baltimore: Williams and Wilkins, 2000: 506-533.
27. Horrow JC: Electrical Safety. In: Kirby RR, Gravenstein N: Clinical Anesthesia Practice, 2nd edition, Philadelphia: Saunders, 2000.
28. Horrow JC: Hematologic Diseases & Their Perioperative Management. In: Bailey PL, Stanley TH (eds.): Update on Cardiovascular Anesthesia. Salt Lake City: Univ. of Utah, 2000: 19-31
29. Horrow JC: Adverse Responses to Protamine. In: Bailey PL, Stanley TH (eds.): Update on Cardiovascular Anesthesia. Salt Lake City: University of Utah, 2000: 41-47
30. Horrow JC: Heparin and Other Glycosaminoglycans. In: Bailey PL, Stanley TH (eds.): Update on Cardiovascular Anesthesia. Salt Lake City: University of Utah, 2000: 121-129
31. Solina A, Ginsberg S, Horrow JC, Hensley FA: Anesthetic Management for Myocardial Revascularization. In: Hensley FA, Martin DE, Gravlee GP: A Practical Approach to Cardiac Anesthesia, 3rd ed., Philadelphia. Lippincott Williams & Wilkins, 2002
32. Shore-Lesserson L, Horrow JC, Gravlee GP: Coagulation Management During and After Cardiopulmonary Bypass. In: Hensley FA, Martin DE, Gravlee GP: A Practical Approach to Cardiac Anesthesia, 3rd ed., Philadelphia. Lippincott Williams & Wilkins, 2002
33. Samama CM, Dietrich W, Horrow J, Taby O, Samama MM: Structure, Pharmacology, and Clinical Use of Antifibrinolytic Agents. In: Bachmann F (ed.): Fibrinolytics and Antifibrinolytics (Handbook of Experimental Pharmacology). Berlin. Springer, 2002
34. Spiess BD, Horrow JC, Kaplan JA: Transfusion Medicine and Coagulation Disorders. In: Kaplan JA (ed.): Kaplan's Cardiac Anesthesia, 5th ed., Philadelphia: Elsevier Saunders, 2006: 937-984
35. Okum G, Horrow JC, Hensley FA: Anesthetic Management for Myocardial Revascularization. In: Hensley FA, Martin DE, Gravlee GP: A Practical Approach to Cardiac Anesthesia, 4th ed., Philadelphia. Lippincott Williams & Wilkins, 2007.
36. Mueksch J, Horrow JC: Coagulation Testing. In: Gravlee GP, Davis RF, Kurusz M, Utley JR (eds.): Principles and Practice of Cardiopulmonary Bypass, 3rd edition, Baltimore: Lippincott Williams and Wilkins, 2007.
37. Shore-Lesserson L, Horrow JC, Gravlee GP: Coagulation Management During and After Cardiopulmonary Bypass. In: Hensley FA, Martin DE, Gravlee GP: A Practical Approach to Cardiac Anesthesia, 4th ed., Philadelphia. Lippincott Williams & Wilkins, 2007
38. Green MS, Okum G, Horrow JC: Anesthetic Management of Myocardial Revascularization. In: Hensley FA, Martin DE, Gravlee GP: A Practical Approach to Cardiac Anesthesia, 5th ed.,

- Philadelphia. Lippincott Williams & Wilkins, 2013; 293-318.
39. Shore-Lesserson L, Malayaman SN, Horrow JC, Gravlee GP: Coagulation Management During and After Cardiopulmonary Bypass. In: Hensley FA, Martin DE, Gravlee GP: A Practical Approach to Cardiac Anesthesia, 5th ed., Philadelphia. Lippincott Williams & Wilkins, 2013; 548-70
 40. Horrow JC, Mueksch JN, Weber N, Green MS: Coagulation Testing. In: Gravlee GP, Davis RF, Hammon JW, Kussman BD (eds.): Cardiopulmonary Bypass and Mechanical Support. Principles and Practice, 4th edition, Philadelphia: Wolters Kluwer, 2016: 449-461
 41. Raphael J, Finley A, Malayaman SN, Horrow JC, Gravlee GP, Shore-Lesserson L: Coagulation Management During and After Cardiopulmonary Bypass. In: Gravlee GP, Shaw AD, Bartels K (eds.): Hensley's Practical Approach to Cardiothoracic Anesthesia, 6th ed., Philadelphia. Wolters Kluwer 2019; 630-655.
 42. Green MS, Okum G, Horrow JC: Anesthetic Management of Myocardial Revascularization. In: Gravlee GP, Shaw AD, Bartels K (eds.): Hensley's Practical Approach to Cardiothoracic Anesthesia, 6th ed., Philadelphia. Wolters Kluwer 2019; 284-311.

Editorials:

1. Horrow JC: Heparin reversal of protamine toxicity: Have we come full circle? [Editorial]. J Cardiothorac Anesth **4**: 539-542, 1990.
2. Horrow JC, Ellison N: Effective haemostasis during cardiac surgery [Editorial]. Can J Anaesth **39**:309-312, 1992.
3. Horrow JC: Highlight on "Autologous platelet-rich plasma does not reduce transfusion of homologous blood products in patients undergoing repeat valvular surgery" (Ereth MH et al., authors) Anesthesiology **79**: 27A, 1993
4. Horrow J: The Emerging Technologies Section is Launched. [Editorial] J Cardiothorac Vasc Anesth **8**:1, 1994
5. Horrow JC: Intraoperative coronary thrombosis: Can protamine be incriminated? [Editorial; comment] J Cardiothorac Vasc Anesth **8**:142-143, 1994
6. Horrow JC: Highlight on "Platelet Factor 4 injection produces acute pulmonary hypertension in the awake lamb" (Kurrek MM et al., authors) Anesthesiology **82**: 31A, 1995
7. Horrow JC: Highlight on "Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery: A double-blind, placebo-controlled study" (Dietrich W et al., authors) Anesthesiology **83**: 29A, 1995

8. Horrow JC: Blood and Haemostasis. *Anaesth Pharmacol Rev* **3**:106, 1995
9. Horrow JC: Highlight on “Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor usage in primary orthotopic liver transplantation” (Boylan JF et al., authors) *Anesthesiology* **85**: 30A-31A, 1996
10. Ahmad M, Cohen JB, Horrow JC: A training model for central venous cannulation for everyman? *J Clin Anesth* 2007; **19**: 489-90
11. Green MS, Horrow JC: Perioperative statin intake for coronary artery bypass graft surgery. Do pleiotropic effects have benefit? *J Clin Anesth* 2008; **20**: 1-3
12. Horrow JC: If nothing goes wrong, is everything all right? [Editorial] *J Cardiothorac Vasc Anesth* 2008; **22**: 653-4

Monographs and Miscellaneous:

1. Horrow JC: Electrical Safety. *Curr Rev Clin Anesth* **4**:26-31, 1983. Reprinted in: *Curr Rev Resp Crit Care* **9**:34-39, 1986.
2. Horrow JC: Systemic Anaphylactic Reactions. *Medical Times* **112**:28-35, 1984.
3. Horrow JC: The 1986 Year Book of Anesthesia and MEDICASSETTE Anesthesia (Book Reviews). *Anesth Analg* **66**:291-292, 1987.
4. Horrow JC: Protamine Allergy Case Discussions. Proceedings of the Blood Transfusion, Hemodilution, and Coagulation Workshop, 11th Annual Meeting of the Society of Cardiovascular Anesthesiologists, Seattle, WA. April, 1989.
5. Horrow JC: In my opinion. Society of Cardiovascular Anesthesiologists Newsletter. April, 1990.
6. Horrow JC: New Therapy of Fibrinolysis. Proceedings of the 12th Annual Meeting of the Society of Cardiovascular Anesthesiologists, Orlando, FL. May, 1990: p. 40
7. Horrow JC: Happy Halloween (Cardiac Crossword). *J Cardiothoracic Anesth* **4**: 668, 1990. (Puzzle solution: *J Cardiothoracic Anesth* **4**: 783, 1990.)
8. Horrow JC: Cardiopulmonary Critical Care, 2nd edition (Book Review). *Crit Care Med* **20**: 1366-1367, 1992.
9. Horrow JC: Protamine Administration and Associated Complications. In: Anticoagulation Management of the Cardiopulmonary Bypass Surgery Patient. Edison, NJ: ITC Educational Services. 1992: p.18-24
10. Horrow JC: Electrical Hazards in the Operating Room. Proceedings of the 8th Henry Ruth

- Conference, Hahnemann University, King of Prussia, PA, October, 1992.
11. Horrow JC: Case study on Excessive post-bypass bleeding. Pathways, The Hemostasis Newsletter (Vol.2, No.5) Edison, NJ: ITC Educational Services. 1992: p. 14
 12. Horrow J: Antifibrinolytics best augment hemostasis after cardiac surgery (Pro / Con). Richmond, VA: SCA Newsletter. February, 1993: pp. 4-5.
 13. Horrow J: Cardiac Physiology. Proceedings of the Minirefreshers Course in Anesthesiology. Philadelphia: Hahnemann University School of Continuing Education. 1993: pp 43-47
 14. Horrow J: Management of Intraoperative Hemostasis. Proceedings, Society of Cardiovascular Anesthesiologists 15th Annual Meeting. Richmond, VA: SCA. 1993: pp 45-50
Monographs and Miscellaneous: (continued):
 15. Horrow JC: Electrical Safety in the Operating Room. Proceedings of the Minirefreshers Course in Anesthesiology at Valley Forge, PA. Philadelphia: Hahnemann University School of Continuing Education. 1994: pp 19-25
 16. Horrow JC: Antifibrinolytic therapy for cardiopulmonary bypass. Proceedings of "Cardiothoracic Anesthesia - 1994," Boston: Harvard Medical School Department of Continuing Education. September, 1994: pp. 1-22
 17. Horrow J: Conflicting Viewpoints on Antifibrinolytic Therapy. Proceedings, Society of Cardiovascular Anesthesiologists 17th Annual Meeting Workshops. Richmond, VA: SCA. 1995: pp 218-222
 18. Horrow J: New strategies for heparin neutralization. Proceedings, Society of Cardiovascular Anesthesiologists 17th Annual Meeting. Richmond, VA: SCA. 1995: pp 114-118
 19. Horrow J: Coagulopathy. In: Proceedings, Update in cardiovascular Surgery, Anesthesia, and Intensive Care 3rd International Symposium (Mortier E, Poelaert J, eds.) Gent, Belgium: Ruksuniversiteit Gent. 1995: 20.
 20. Horrow JC: Update on antifibrinolytic therapy. In: Proceedings, Society of Cardiovascular Anesthesiologists 18th Annual Meeting Workshops. Richmond, VA: SCA. 1996: pp 255-258
 21. Horrow JC: Determinants of cost during cardiac surgery: Hematological problems. In: Proceedings, Society of Cardiovascular Anesthesiologists 19th Annual Meeting Workshops. Richmond, VA: SCA. 1997: p 153
 22. Horrow JC: Heparinase I as an Alternative to Protamine. In: Proceedings, 4th Annual Update on Cardiopulmonary Bypass. Richmond, VA: Society of Cardiovascular Anesthesiologists. 1999: p 80
 23. Horrow JC: Use of heparin and heparan lyases in cardiovascular medicine. In: Proceedings, Innovations in Cardiovascular Medicine. SMi London. 1999: p 40

24. Horrow JC: Neutralase Reversal of Heparin Anticoagulation. In: Proceedings, Beyond Heparin: Novel Anticoagulants & Emerging Applications. Cambridge Healthtech Institute: Cambridge, MA: 1999.
25. Horrow JC, Mazer CD: Audience Response System: Antifibrinolytic Therapy. Richmond, VA: Society of Cardiovascular Anesthesiologists Newsletter. August, 1999: pp 5-6
26. Horrow JC, Chamchad D: CON: Monitoring heart rate variability adds a significant incremental value in cardiovascular surgery. Richmond, VA: Society of Cardiovascular Anesthesiologists Newsletter. February, 2006
27. Phon H, Jaffe J, Horrow J. Perioperative management of locked-in syndrome from acute ischemic stroke. Poster MC218, 2007 Annual Meeting, American Society of Anesthesiologists.

NOTE: Miscellaneous list and poster presentations not maintained beyond 2007.

BIBLIOGRAPHY (continued):

Abstracts: (Every abstract listed has been peer-reviewed and presented at a scientific meeting.)

1. Horrow JC, Bartkowski RR: Cold Reduces Potency of Curare; Not Pancuronium. *Anesthesiology* **55**:A217, 1981.
2. Bartkowski RR, Horrow JC: Pancuronium Washout as a Model of Rapid Degradation. *Anesthesiology* **55**:A204, 1981.
3. Metz S, Horrow JC, Balcar I: A Controlled Comparison of Technics for Internal Jugular Vein Cannulation using Ultrasonography. Presented at the 6th Annual Meeting of the Society of Cardiovascular Anesthesiologists, Boston, Massachusetts, May, 1984.
4. Maddi R, Concepcion M, Horrow J, Mark J, Covino B, Murray E: Evaluation of EMLA as a Topical Anesthetic. *Regional Anesthesia* **10**:39, 1985.
5. Horrow JC, Jaffe JR, Rosenberg H: Is the Dial-A-Flo a Clinically Useful Device? A Laboratory Study. Presented at the 8th Annual Meeting of the Society of Cardiovascular Anesthesiologists, Montreal, PQ, Canada, April, 1986.
6. Horrow JC, Metz S, Thickman D, Frederic M: Prior Carotid Surgery Does Not Affect Ability to Locate the Internal Jugular Vein. *Anesth Analg* **66**:S84, 1987.
7. Horrow JC, Feinerman L, Colonna-Romano P, Seitman D, Brajer J, Rosenberg H: Urine Output Affects Urinary Catheter Temperature During Rapid Rewarming. *Anesth Analg* **66**:S83, 1987.
8. Hlavacek J, Horrow J, Strong M, Brodsky I, Bledsoe L, Ross E: Prophylactic Tranexamic Acid Decreases Bleeding Following Cardiac Surgery. Presented at the 10th Annual Meeting of the Society of Cardiovascular Anesthesiologists, New Orleans, April, 1988.
9. Horrow J, DiGregorio GJ, Barbieri E, Rupp E, Ruch EK: Nitroprusside is Compatible with Nitroglycerine and Dobutamine in IV Admixtures. Presented at the 10th Annual Meeting of the Society of Cardiovascular Anesthesiologists, New Orleans, April, 1988.
10. Padolina RM, Rosenberg H, Horrow JC, Jaffe J: Open Randomized Evaluation of Sufenta and Sublimaze in General Surgical Procedures. Presented at the 9th World Congress of Anesthesiology, Washington DC, May, 1988.
11. Collier W, Hlavacek J, Horrow JC, Goldman S, Goel IP: Prophylactic Tranexamic Acid Decreases Blood Loss after Extracorporeal Circulation. *Anesthesiology* **69**:A135, 1988.
12. Van Riper D, Horrow JC, Colonna-Romano P, Goldman S: Mixed Venous Oximetry Following Cardiac Arrest. *Anesthesiology* **69**:A134, 1988.

13. Nyhan D, Weiss M, Chen B, Blanck T, Horrow J, Levy J, Roizen M, Adkinson F, Hirshman C: Protamine-specific IgE antibodies as predictors of adverse reactions in insulin-dependent diabetic patients. *Anesthesiology* **69**:A9, 1988.
14. Van Riper D, Horrow JC, Schwartz AJ, Mazala M: Protamine on Ice? Presented at the 11th Annual Meeting of the Society of Cardiovascular Anesthesiologists, Seattle, April, 1989.
15. Amin FB, Horrow JC, Ross E: Does Nitroglycerin antagonize heparin's activity by inhibiting anti-thrombin III? Presented at the 11th Annual Meeting of the Society of Cardiovascular Anesthesiologists, Seattle, April, 1989.
16. Allen G, Horrow JC, Rosenberg H: Is forehead liquid crystal temperature a "core" temperature? Presented at the 11th Annual Meeting of the Society of Cardiovascular Anesthesiologists, Seattle, April, 1989.
17. Wiener L, Horrow JC, Strong MD, Brodsky I, Osborne D: When during open heart surgery should anti-fibrinolytic drugs be administered? Presented at the 11th Annual Meeting of the Society of Cardiovascular Anesthesiologists, Seattle, April, 1989.
18. Horrow JC, Wiener LB, Osborne D: Fibrin split products predict blood loss after cardiac surgery. *Anesthesiology* **71**: A3, 1989.
19. Wiener LB, Horrow JC, Fox D: Increased fibrin split products with a passive flow membrane oxygenator. *Anesthesiology* **71**: A2, 1989.
20. Rosenberg H, Horrow J, Polonsky B: Do faculty advisor programs work? *Anesthesiology* **71**: A967, 1989.
21. Horrow JC, Van Riper DF, Strong MD, Parmet JL, Brodsky I, Osborne D: Tranexamic acid, not desmopressin or both drugs, decreases bleeding after cardiac surgery. Presented at the 12th Annual Meeting, Society of Cardiovascular Anesthesiologists, Orlando, May, 1990.
22. Horrow JC, Van Riper DF, Strong MD, Brodsky I, Osborne D: Tranexamic acid, not desmopressin or both drugs, decreases bleeding after cardiac surgery. *Fibrinolysis* **4**: 181, 1990.
23. Van Riper DF, Horrow JC, Osborne D: Is the thromboelastograph a clinically useful predictor of blood loss after bypass? *Anesthesiology* **73**:A1206, 1990.
24. Horrow JC, Van Riper DF, Parmet J, Strong MD, Brodsky I, Osborne D: Tranexamic acid, not desmopressin or both, decreases bleeding after open heart surgery. *Anesthesiology* **73**:A63, 1990.
25. Abrams JT, Horrow JC, Storella RJ, Van Riper DF, Lambson DL, Rawa J: Priming dose of pancuronium does not attenuate chest wall rigidity from sufentanil. *Anesthesiology* **73**:A148, 1990.

26. Rosenberg H, Horrow JC, Polonsky B: Faculty advisors: Role models? Employment counselors? *Anesthesiology* **73**:A1036, 1990.
27. Colonna P, Lingaraju N, Mazala M, Horrow JC: Clinical sensitivity and specificity of epidural test dose in obstetrics as a marker of intravascular injection. *Anesthesiology* **73**:A925, 1990.
28. Horrow JC, Van Riper DF, Strong MD, Parmet JL, Brodsky I, Osborne D: Desmopressin does not decrease bleeding in patients taking aspirin. Presented at the 13th Annual Meeting of the Society of Cardiovascular Anesthesiologists, San Antonio, May, 1991.
29. Siler JN, Horrow JC, Rosenberg H: The impact of intravenous anesthesia with propofol on postanesthesia care unit (PACU) outcome. Presented at the Annual Meeting of the Society for Ambulatory Anesthesia, San Diego, May, 1991.
30. Rosenberg H, Polonsky B, Horrow J, Padolina R: Residency Program Interviews: Candidates Perceptions. *Anesthesiology* **75**:A877, 1991.
31. Okum G, Colonna-Romano P, Horrow JC: Vomiting after Alfentanil - Effect of Dosing Method. *Anesthesiology* **75**:A2, 1991.
32. Colonna-Romano P, Horrow JC, Baker D: Anesthesia, Not Paralysis, Increases Mixed Venous O₂. *Anesthesiology* **75**:A162, 1991.
33. Horrow J, Van Riper D, Parmet J, Osborne D: Desmopressin does not Decrease Bleeding after Aspirin. *Anesthesiology* **75**:A985, 1991.
34. Horrow J, Van Riper D, Parmet J, Whooley P: What Dose of Tranexamic Acid is Optimally Hemostatic? *Anesthesiology* **75**:A986, 1991.
35. Horrow J, Levit L, Freeland C, Began S, Henry W: Do Skin Tests Correlate with Antibodies to Protamine? *Anesthesiology* **75**:A61, 1991.
36. Balas AZ, DiPersio DM, Horrow JC, Khalidi N, Miller BE, Pesko L, Soukup JR, Tsiu SJ, Pierce JE: Compatibility of critical care medications in a multiple-line infusion system. Presented at the Annual Meeting of the American Society of Hospital Pharmacists, New Orleans, December, 1991
37. Van Riper D, Horrow J, LaDuca F, Nyhan D: An In Vitro Test to Predict Heparin Response. *Anesth Analg* **74**:S331, 1992.
38. Lingaraju N, Colonna P, Horrow JC, Strong M: Hemodynamic Effects of Warm Cardiac Irrigation. *Anesth Analg* **74**:S189, 1992.
39. Siler JN, Horrow JC, Rosenberg H: Propofol Reduces Prolonged PACU Stay. *Anesth Analg* **74**:S291, 1992.

40. Parmet JL, Pharo G, Orlando D, Kuralis D, Horrow JC: ST Segment Depression During LIMA Dissection: Artifact or Ischemia? Presented at the 14th Annual Meeting of the Society of Cardiovascular Anesthesiologists, Boston, May, 1992.
41. Bennett JA, Horrow JC, Van Riper DF, Chalfin R, Storella RJ, Rawa J: Ablating Opioid-induced Rigidity: Pancuronium or Pipecuronium? In: 1992 Annual Meeting Program. Society of Cardiovascular Anesthesiologists: Richmond, VA. 1992: p. 289.
42. Bennett JA, Horrow JC, Fynes M: Dialyzing banked blood during rapid transfusion. *Anesthesiology* **77**:A539, 1992.
43. Parmet JL, Pharo G, Kuralis D, Horrow JC: ST segment depression during LIMA dissection: Artifact or ischemia? *Anesthesiology* **77**:A95, 1992.
44. Horrow JC, Bennett J, Van Riper D, Storella, RJ: Opioid induced rigidity and twitch response: A comparison of pancuronium and pipecuronium. *Anesthesiology* **77**:A940, 1992.
45. Pan CM, Van Riper DF, Horrow J, LaDuca F: Non-linearity of heparin anticoagulation activity in response to multiple heparin dose. *Blood* **80** (Suppl I):2032, 1992
46. Hauser A, Okum G, Smetlz H, Horrow J: Alfentanil v. fentanyl with propofol for laparoscopy. *Anesth Analg* **76**:S138, 1993.
47. Okum G, Hauser A, Horrow J, Keykhah M, Begen S: Sufentanil pharmacokinetics during tourniquet use. *Anesth Analg* **76**:S309, 1993.
48. Horrow JC, Van Riper DF, Strong MD, Malik N: Tranexamic acid is hemostatic when administered only during heparinization. In: 1993 Annual Meeting Program. Society of Cardiovascular Anesthesiologists: Richmond, VA. 1993: p. 259.
49. Parmet JL, Horrow JC, Rosenberg H, Berman A: The pulmonary hemodynamic effects of echogenic emboli released upon tourniquet deflation during total knee arthroplasty. Proceedings of the Annual Meeting of the Association of University Anesthesiologists, Winston-Salem, NC: 1993: Poster #30.
50. Horrow J, Malik N, Pan C-M, Lodder C, LaDuca F: Fibrinogen measurement for hemostasis assessment during cardiac surgery. *Thromb Haemostas* **69**:984, 1993
51. Van Riper D, Horrow J, Pan C-M, LaDuca F: Anticoagulant activity in response to sequential heparin doses is non-linear. *Thromb Haemostas* **69**:2026, 1993
52. Van Riper DF, Horrow J, Strong MD, Malik N: Tranexamic acid is hemostatic when administered only during heparinization. *Anesthesiology* **79**:A93, 1993
53. Parmet JL, Horrow J: Cardiopulmonary bypass changes the left ventricular pressure-volume

- relationship: a TEE study. *Anesthesiology* **79**:A72, 1993
54. Parmet JL, Horrow J, Rosenberg H: Echogenic emboli always occur upon tourniquet deflation during total knee arthroplasty. *Anesthesiology* **79**:A1067, 1993
 55. Storella RJ, Kandell RB, Horrow JC, Polansky M: Opioid anesthesia and nervous control of the heart. Dynamical systems in the neurosciences: Satellite symposium, Annual Meeting, Society for Neuroscience, Washington DC, November, 1993
 56. Metz S, Horrow JC: Methylene blue does not neutralize heparin after cardiopulmonary bypass. In: 1994 Annual Meeting Program. Society of Cardiovascular Anesthesiologists: Richmond, VA. 1994: p. 339.
 57. Horrow JC, Rosenberg H: Price stickers do not alter drug usage. *Anesthesiology* **81**:A1308, 1994.
 58. Parmet JL, Horrow JC, Pharo G, Collins L, Keykha M, Okum G: Does extramedullary-guided total knee arthroplasty reduce embolic showers? *Anesthesiology* **81**:A1217, 1994.
 59. Bennett JA, Horrow JC: Activated coagulation time: One tube or two? *Anesthesiology* **81**:A86, 1994.
 60. Abrams J, Horrow JC, Bennett J, Van Riper D, Bellwoar C, Katta P, Storella R: Sedated fiberoptic intubation eliminates sufentanil induced rigidity. *Anesthesiology* **81**:A190, 1994.
 61. Metz S, Horrow JC, Bellwoar C, Goel IP, Kuretu MR: Failure of methylene blue to neutralize heparin after cardiopulmonary bypass. *Anesthesiology* **81**:A191, 1994.
 62. Storella RJ, Kandell RB, Polansky M, Horrow JC: Approximate entropy, a non-linear statistic, detects effects of opioid anesthesia on heart rate variability. *Anesthesiology* **81**:A150, 1994.
 63. Bennett J, Abrams J, Horrow JC, Van Riper DF: Difficult ventilation after opioid induction is caused by laryngospasm. *Anesthesiology* **83**: A74, 1995
 64. Miller F, Parmet JL, Horrow JC, Berman AT: Total knee arthroplasty without a pneumatic tourniquet reduces embolic showers. *Anesthesiology* **83**: A1112, 1995
 65. Storella RJ, Horrow JC, Kandell RB, Zietz S: Modification of the approximate entropy measure of heart rate variability. *Anesthesiology* **83**: A99, 1995
 66. Pan CM, Jobs D, Van Riper D, Ogilby D, Lin C-Y, Horrow J, Blumenthal R, Mendoza M, LaDuca F: A modified microsample ACT assay for heparin monitoring. *Thromb Haemostas* **73**: A296, 1995. [Also presented at AmSECT 33rd International Conference, Orlando, FL, 1995 and 15th Annual Meeting of San Diego Cardiothoracic Surgery Symposium, San Diego, CA, 1995]
 67. LaDuca F, Pan CM, Jobs D, Blumenthal R, Van Riper D, Ogilby JD, Horrow J: Evaluation of

- clinical utility of ACT+ test. Presented at AmSECT 34th International Conference, Dallas, TX, 1996
68. Storella RJ, Shi Y, Wood HW, V-N Nguyen, Polansky M, Horrow JC: Different characteristics of heart rate variability are altered by anesthesia and cardiac surgery. *Anesthesiology* **85**: A155, 1996.
 69. Recker D, Broughton R, Gravlee G, Heres E, Hildebrand K, Marquez J, Despotis G, Bennett J, Lewis P, Van Riper D, Horrow J: Heparinase I (Neutralase™) reverses the heparin induced prolongation of activated clotting time (ACT) in patients undergoing cardiopulmonary bypass grafting (CABG). Presented at 15th Annual Symposium, Clinical update in Anesthesiology and Advances in techniques of cardiopulmonary bypass, Acapulco, Mexico, 1997 - **1st prize**
 70. Heres E, Van Riper D, Marquez J, Hildebrand K, Lewis P, Bennett J, Recker D, Broughton R, Horrow J, Gravlee G: Heparin reversal with heparinase I (Neutralase™) in coronary artery bypass patients. *Anesth Analg* **84**: SCA32, 1997
 71. Van Riper DF, Heres E, Bennett J, Horrow J, Marquez, J: Neutralase 7 µg/kg reverses heparin-induced prolongation of ACT better than 5 µg/kg in patients undergoing CABG. *Anesthesiology* **87**: A95, 1997
 72. Schwartz AJ, Blank L, Horrow J, Campbell FW: Are anesthesiology residents educated to be professionals? *Anesthesiology* **87**: A950, 1997
 73. Okum G, Keykhah M, Horrow J, Storella RJ: Is reversal of mivacurium detrimental? *Anesthesiology* **87**: A845, 1997
 74. Strong M, Bennett J, Gravlee GP, Tardiff B, Lubner J, Schneider J, Barragry T, DiSanto AR, Carter F, Broughton RL, Goldstein NH, Recker DP, Horrow JC: Efficacy and pharmacokinetics of Neutralase™ in CABG. *Anesth Analg* **86**: SCA28, 1998.
 75. Heres E, Strong MD, Couper G, Kennedy D, Johnson GL, Broughton R, Heft R, Horrow JC: Antibodies recognizing heparinase-1 change neither efficacy nor safety. *Anesth Analg* **90**: SCA17, 2000
 76. Gravlee GP, Vester SR, Regensburger D, Boyce S, Gold JP, Heft R, Horrow JC: Heparinase-1 vs. protamine for heparin neutralization after bypass. *Anesth Analg* **90**: SCA18, 2000.
 77. Fitch JCK, Bleese N, Osborne J, El-Banayosy A, Capdeville M, Heft R, Horrow JC: Hemodynamic effects of heparinase-1 and protamine following heparin neutralization during CABG. Presented at 7th International Congress of Cardiothoracic and Vascular Anesthesia, Québec City, Canada, June, 2000.
 78. Schwann NM, Horrow JC, Chamchad D, Strong MD, Guerraty A: Renal dysfunction in Multivessel myocardial revascularization. Does the off pump technique (OPCAB) confer renal protection? *Anesthesiology* **95**: A248, 2001

79. Chamchad D, Arkoosh V, Horrow JC, Buxbaum J Kresh Y: Risk stratification for hypotension in obstetric patients undergoing spinal anesthesia. *Anesthesiology* **97**:A-1061, 2002
80. Katona BG, Larimer DF, Horrow JC, Peters G: The effect of oral anticoagulant therapy on event rates in patients after acute coronary syndromes: A systematic review. *Pharmacotherapy* **22**: 1327 A19, 2002.
81. Katona BG, Peters G, Chelune P, Horrow JC, Francis CW: Rates of thromboembolism and bleeding in studies of oral anticoagulation. *Blood* **100**: 705a, 2002.
82. Burton EC, Katona BG, Peters G, Horrow JC, Francis CW: Rates of recurrent thromboembolism and bleeding in venous thromboembolism patients treated with long-term LMWH. *J Thromb Haemostas* **1**(supplement 1):1418, 2003.
83. Chamchad D, Jung JH, Djaiani G, Horrow J, Arkoosh V: Heart Rate Variability: Predictor Of Cardiac Arrhythmia After CABG Surgery. *Anesthesiology* **101**:A-241, 2004
84. Baruch L, Gage B, Persson M, Zabalgoitia M, Juul-Möller S, Labovitz A, Horrow J: Which is the most accurate stroke prediction scheme in atrial fibrillation patients treated with anticoagulants? A comparison of 5 risk stratification schemes. *Circulation (AHA abstract)*: 2004
85. Douketis J, Arneklev K, Goldhaber S, Spandorfer J, Halperin F, Horrow J: Ximelagatran versus warfarin: A comparison of bleeding outcomes in patients with nonvalvular atrial fibrillation. *Blood* **104(11)**: #1765, 2004
86. Douketis J, Arneklev K, Goldhaber S, Spandorfer J, Halperin F, Horrow J: Risk factors for bleeding in patients with nonvalvular atrial fibrillation who are receiving anticoagulant therapy with ximelagatran or warfarin. Findings from the SPORTIF III and V trials. *Blood* **104(11)**: #528, 2004
87. Gage B, Labovitz A, Persson M, Zabalgoitia, Baruch L, Juul-Moller S, Horrow J. Predictors of Stroke in 7329 Patients with Atrial Fibrillation Treated with Anticoagulant Therapy in the SPORTIF III and V Trials. AHA Stroke Scientific Session, New Orleans, February 2005.
88. Flaker G, Gruber M, Connolly S, Goldman S, Horrow J. Effect of aspirin treatment on stroke prevention and bleeding in patient anticoagulated for stroke prophylaxis in atrial fibrillation. *JACC* 2005; [ACC meeting].
89. Liddle R, Toskes P, Stong D, Ghali J, Horrow J. Trypsin inhibition with ximelagatran does not increase pancreatic volume. *Dig Disease Week*, 2005.
90. Juul-Moller S, Baruch L, Gage B, Persson M, Zabalgoitia M, Labovitz A, Horrow J: Indicators of endothelial injury predict stroke in patients anticoagulated for stroke prevention in atrial fibrillation. *Heart Rhythm Society*, 2005.
91. Chamchad D, Horrow J, Samuels L, Nakhmchik L, Suter F, Boova R, Goldman S: Very early extubation (VEE) after cardiac surgery associates with decreased ICU and hospital stays. *Anesth Analg* **100**: SCA49, 2005
92. Chamchad D, Horrow J, Samuels L, Sutter F, Goldman S: Associations of Very Early Extubation after Cardiac Surgery with Re-Intubation, Atrial Fibrillation, and Length of Stay. *Anesthesiology* **103**: A-417, 2005

93. Chamchad D, Horrow JC, Nakhamchik L, Aronzon B, Sauter J. Effect of glycopyrrolate on heart rate variability during spinal anesthesia for Cesarean section. *Anesthesiology* 2006; **105**: A-1661
94. Chamchad D, Horrow JC, Perez-Villabona C, Roberts N. Prophylactic glycopyrrolate prevents bradycardia after spinal anesthesia. *Anesthesiology* 2006; **105**: A-1660
95. Chamchad D, Roberts N, Horrow JC, Aronzon B, Sauter J, Perez-Villabona C, Bedenko E. Prophylactic glycopyrrolate prevents bradycardia after spinal anesthesia for Cesarean section. *Anesthesiology* 2007; **106** (Supp 1):58 [Abstract A-99]
96. Chamchad D, Samuels L, Sutter F, Zonshayn A, Djaini G, Horrow J: Heart rhythms and rate variability in patients undergoing off versus on-pump coronary surgery. *Anesthesiology* 2007; **107**: A-1263
97. Chamchad D, Horrow J, Roberts N, Aronzon B, Sauter J. Prophylactic Glycopyrrolate prevents Bradycardia After Spinal Anesthesia. *Anesthesiology* 2007; **107**: A-1770
98. Hoffman C, Horrow J, Izzetoglu K, Levitt J, Hua Y, Goyal G. Functional near infrared spectroscopy as a monitor for depth of anesthesia. *Anesth Analg* 2008; **106**:A-1082
99. Goyal G, Horrow J. Evaluation of morphine sparing effects of gabapentin for relief of postoperative pain in patients undergoing lumbar laminectomy. A double-blind study. *J Pain* 2008
100. Goyal G, Brodsky M, Munoz-Allen M, Aloï J, Horrow J: Unusual case of bilateral brachial plexus injury related to ramping. *Society for Ambulatory Anesthesia* 2008.

NOTE: Abstract list not maintained beyond 2008.

Letters to the Editor:

1. Bartkowski RR, Horrow JC: Temperature and the Potency of Relaxants. *Anesth Analg* **60**:455, 1981.
2. Horrow JC, Laucks SO: Preventing Air Embolism while Inserting Central Catheters. *Anesthesiology* **57**:350, 1982.
3. Horrow JC: Another (non-vulgar) Use of the Finger. *Anesthesiology* **58**:198, 1983.
4. Horrow JC: Brachial Plexus Injury. *Ann Thorac Surg* **37**:660-661, 1984.
5. Horrow JC, Lambert DL: Optimal Interval between curare pretreatment and succinylcholine. *Can Anaesth Soc J* **32**:452, 1985.
6. Mazala M, Horrow JC, Storella RJ: Hypothermia and the action of non-depolarizing neuromuscular blocking agents. *Anaesthesia* **43**:162, 1988.
7. Horrow JC: Use of the precordial stethoscope. *J Clin Monitoring* **4**:230-231, 1988.
8. Horrow JC: Insidious balloon failure. *J Cardiothoracic Anesth* **3**: 252-253, 1989.
9. Amin FB, Horrow JC: Nitroglycerin antagonism of heparin. *Anesthesiology* **73**:193-4, 1990
10. Horrow JC: Efficacy of tranexamic acid in surgical bleeding. *Transfusion* **32**:292, 1992.
11. Horrow JC: "Heparin Allergy" and Cardiopulmonary Bypass: Invited commentary. *J Cardiothor Vasc Anesth* **7**:505-506, 1993
12. Okum GS, Horrow J, Colonna-Romano P: Vomiting after alfentanil anesthesia (response). *Anesth Analg* **77**:407-408, 1993
13. Horrow JC: Iloprost et thrombopénie a l'héparine. *Ann Fr Anesth Réanim* **12**:612, 1993
14. Parnet JL, Horrow J, Rosenberg H: Fat embolism syndrome. *N Engl J Med* **330**:642-643, 1994.
15. Horrow JC, Van Riper DF: Anticoagulation for transluminal angioplasty: How much? *Am J Cardiol* **73**:933, 1994.
16. Horrow JC, Strong MD, Van Riper DF: Tranexamic acid after bypass: Too late to help? *J Thorac Cardiovasc Surg* **107**:1375-1376, 1994.
17. Horrow JC: Antifibrinolytic therapy: Treat whom and with what? *J Clin Anesth* **7**: 690, 1995
18. Bennett JA, Horrow JC: A method to avoid accidental arterial placement of an introducer sheath. *J Clin Anesth* **8**: 171-172, 1996

19. Bennett JA, Abrams J, Van Riper DF, Horrow JC: In reply to Small doses of sufentanil will produce violent coughing in young children. *Anesthesiology* **89**: 272, 1998.
20. Horrow JC, Horrow MM: Age and Common Bile Duct Diameter. *Radiology* **225**: 921-2, 2002.
21. Horrow JC: Heparinase I as an alternative to protamine. *Anesth Analg* **95**:501-2, 2002
22. Olsson SB for the Executive Steering Committee: Ximelagatran or warfarin in atrial fibrillation? *Lancet* **363**: 736, 2004 [Horrow JC is a member of the Executive Steering Committee and a contributing author to this letter.]
23. Olsson SB for the Executive Steering Committee: Aspirin bias in SPORTIF III trial. *Lancet* **363**: 2091, 2004. [Horrow JC is a member of the Executive Steering Committee and a contributing author to this letter.]
24. Chamchad D, Finnegan M, Horrow JC. Spinal, but not epidural anesthesia, for pubic symphysis separation. *Anesth Analg* 2006; **103**: 258.
25. Albers GW, Diner HC, Frison L, Grind M, Horrow J, Nevinson M, Olsson SB, Patridge S, Petersen P, Vahanian A, Halperin JL. Trials and tribulations of noninferiority. The ximelagatran experience. *JACC* 2006; **48**: 1058.

[End of Document]